VolitionRx Closes $16.5 Million Confidentially-Marketed Public Offering

Represented VolitionRx in its closing of a confidentially-marked underwritten public offering of common stock, resulting in gross proceeds of $16.5 million, including the subsequent exercise of the overallotment option in full, before deducting underwriting commission and other offering expenses payable by VolitionRx. Prime Executions, Inc. dba Freedom Capital Markets acted as the book-running manager of the offering, and Bancroft Capital, LLC acted as co-manager. 

VolitionRx is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including certain cancers and diseases associated with NETosis such as sepsis and COVID-19.